Double-blind placebo-controlled phase 2 study to evaluate the safety & tolerability of PPS in subjects with MPS VI
Source: Giugliani, R. et. al.
February 10, 2022
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this update.